Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its ...
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. Founded in 2013 with support from Third Rock Ventures, Voyager is headquartered in Cambridge, Massachusetts, and went public in 2015. The company specializes ...Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of and ultimately cure neurological diseases. Founded in 2013 with support from Third Rock Ventures, Voyager is headquartered in Cambridge, Massachusetts, and went public in 2015. The company specializes in gene therapy, using adeno-associated virus (AAV) vectors to deliver genetic treatments. Its lead clinical asset, VY-AADC, is a gene therapy for Parkinson's disease, currently in Phase 1 clinical trials. The preclinical pipeline includes VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, VY-FXN01 for Friedreich's ataxia, and programs targeting tauopathies like Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as spinal muscular atrophy. Voyager has formed strategic collaborations with major pharmaceutical companies, including Neurocrine Biosciences, Pfizer, and Novartis Pharma, to advance the research, development, and commercialization of its gene therapy products. Financially, the company has a market capitalization of approximately $194 million and has invested heavily in R&D, with R&D expenses to revenue over 3.4 times, reflecting its strong focus on innovation. Despite negative profitability metrics, the company maintains a solid current ratio of 7.5, indicating good short-term liquidity. Key leadership includes CEO Alfred W. Sandrock Jr., a physician-scientist with extensive experience in neurology and drug development. Voyager's vision is to provide transformative treatments for millions affected by neurological disorders, and its state-of-the-art headquarters includes advanced research and process development laboratories. The company continues to advance its pipeline and platform technologies, focusing on capsid engineering and genetic medicine to overcome delivery challenges in the brain.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$40.4M
-49.5%
+22.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-119.7M
-84.2%
+12.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-227.6%
-327.6%
+56.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-326.6%
-213.7%
+28.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-296.5%
-265.0%
+28.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-135.1M
-617.2%
+22.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-334.5%
-1321.2%
+36.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
18.6%
+27.6%
+6.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
7.64x
+37.4%
-10.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
